- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report. (Pubmed Central) - Dec 21, 2022 A 57-year-old woman with metastatic adenocarcinoma of the colon, receiving FOLFIRI and Cetuximab as a first-line treatment, presented with a severe erythematous rash and xerosis resistant to local treatment with moisturizing emollients...This is a life-threatening cutaneous toxicity of cetuximab with secondary bacterial infection. Early recognition of cutaneous side effects of EGFR inhibitors is important to prevent such type of toxicities.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
P2 data, Journal, Combination therapy: A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study. (Pubmed Central) - Dec 18, 2022 Resistance after initial response to targeted therapy can be either adaptive (e.g., epigenetic, or transcriptomic alterations) or acquired (selective genetic alterations - e.g., activating de novo mutations) resistance. It is of great importance to untangle these complex mechanisms of resistance in patients with BRAF V600E mutated mCRC to improve treatment strategies in the future potentially even further.
- |||||||||| Journal, PD(L)-1 Biomarker, IO biomarker: Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy. (Pubmed Central) - Dec 17, 2022
Then the patient received the sixth line of treatment, camrelizumab/lorlatinib, for 9 antitumor cycles, resulting in PR...To our knowledge, this is the first documented case of cCR in a patient with ALK-positive advanced lung adenocarcinoma treated with multiple lines of therapy followed by surgical treatment. This case reveals the possible survival benefit of immunotherapy after multiple line treatment in ALK-positive advanced lung adenocarcinoma, indicating that it is possible find new therapeutic targets based on NGS molecular detection and provide precise therapeutic strategies for clinical practice when drug resistance or progression occurs in cancer therapy.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion date, Metastases: S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 16, 2022 P2/3, N=174, Active, not recruiting, The trial registration number was ChiCTR2100041643. Trial completion date: Oct 2022 --> Jun 2023
- |||||||||| Kineret (anakinra) / SOBI
Single Institution Review of Anakinra for the Management of Icans in CAR T-Cell Therapy (World Center Marriott Cypress Foyer Alcove 1/ Cypress Foyer Alcove 2; In-Person) - Dec 15, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_881; In our pt cohort, pts with delayed onset of ICANS often were steroid refractory, necessitating the use of Anakinra. It is unclear whether the use of Anakinra impacted the duration of ICANS but was not associated with an increased risk of infection.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer. (On Demand | Level 1, West Hall; Poster Board No. P13) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_933; As of Sep 20, 2022, 9 patients were enrolled. Clinical trial information: jRCTs031210510.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107. (On Demand | Level 1, West Hall; Poster Board No. P7) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_928; P2 The study activated across the United States in June 2022 and as of September 2022 has enrolled 2 of 75 planned participants. Funding: NIH/National Cancer Institute grants U10CA180888, U10CA180819, U10CA180820, U10CA180821, U10CA180868; and in part by The Hope Foundation for Cancer Research STrS award.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E–mutant metastatic colorectal cancer. (On Demand | Level 1, West Hall; Poster Board No. P6) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_927; As of September 19, 2022, 8 patients have been enrolled. Clinical trial information: jRCTs031210511.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC). (On Demand | Level 1, West Hall; Poster Board No. C7) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_716; We included mCRC patients with RAS/BRAF wild-type tumors receiving EGFR mAb (cetuximab or panitumumab) in 1st line (1L, n = 248) or in 2L+ of therapy (n = 2,118). RAS/RAF WT mCRC patients with baseline alterations in RTK genes have less favorable outcomes on EGFR inhibitors (intrinsic resistance), and post-EGFR mAb samples (acquired resistance) converge around RTK and MAPK alterations, particularly MET, in real-world data.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
First-line anti-EGFR or anti-VEGF therapy, tumour sidedness, and survival: Results from the South Australian (SA) Metastatic Colorectal Cancer (mCRC) Registry. (On Demand | Level 1, West Hall; Poster Board No. B17) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_706; The survival seen for Pmab and Cmab was almost identical for both right and left primary tumours. When comparing Pmab, Cmab and bev as first-line therapy, there was no significant difference in mOS for both left- and right-sided CRC.
- |||||||||| Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer. (On Demand | Level 1, West Hall; Poster Board No. A11) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_680;
In this comparative effectiveness study of a cohort of Medicare recipients and the Bronx population, with mCRC, biochemotherapy was associated with an improvement in OS, especially in the 1st year. Patients receiving biochemotherapy are more likely to receive further lines of chemotherapy upon disease progression.
|